Compare Moderna, Inc. (MRNA) vs Norfolk Southern Corporation (NSC) Price & Performance

Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.

The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.

Norfolk Southern (NSC) trades at $316.99, up 1.21% with bullish technical indicators and strong institutional support. The company demonstrates solid fundamentals with consistent earnings beats, a 21.02% net income margin, and robust cash flow from operations. Recent news highlights momentum for the proposed Union Pacific merger, with regulatory review advancing and over 500 customer endorsements supporting the combination's potential benefits.

NSC presents a favorable risk-reward profile with analyst consensus target of $361.86 offering 14% upside. Key opportunities include freight share gains from trucking and merger synergies, while risks involve fuel price pressures and regulatory hurdles for the combination. The stock remains well-positioned for long-term growth with dividend stability.